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Abstract
Highly active antiretroviral therapy (HAART) requires strict adherence to achieve optimal clinical
and survival benefits. A study was done to explore the factors affecting HAART adherence among
HIV positive adults by reviewing routinely collected patient information in the Centre for the
AIDS Programme of Research in South Africa’s (CAPRISA) AIDS Treatment Programme.
Records of 688 patients enrolled between 2004 and 2006 were analysed. Patients were considered
adherent if they had taken at least 95% of their prescribed drugs. Generalized estimating equations
were used to analyse the data. The results showed that HAART adherence increased over time,
however, the rate of increase differed by some of the socio-demographic and behavioural
characteristics of the patients. For instance, HAART adherence increased in both urban and rural
treatment sites over time, but the rate of increase was higher in the rural site. This helped identify
sub-populations, such as the urban population, that required ongoing adherence counseling.
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Introduction
Highly active antiretroviral therapy (HAART) has dramatically reduced morbidity and
mortality among HIV-infected individuals1–3, and requires strict adherence to attain optimal
clinical and survival benefits.4–6 Patients who take 95% or more of their prescribed
medication benefit more from treatment than those who take less than 95%.4 Identifying and
overcoming factors that reduce adherence to HAART is therefore critical if optimal clinical
and survival benefits are to be attained. Optimal adherence to HAART is often influenced by
a variety of factors, including social, demographic, economic and behavioural.7,8 There
have however been inconsistent findings regarding the association between adherence,
demographic and economic factors. For instance, some studies have shown an association
between adherence and age,9,10 while others did not find such a relationship.11 Income has
also been associated with HAART adherence in some studies,12,13 while others have
concluded that there was no link between the two.14 Social factors that include family
support have been consistently associated with adherence.15 The fact that associations
between adherence and demographic and economic factors are observed inconsistently
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highlights the need for an evaluation and understanding of how these factors interact among
themselves, and how they interact with other social, clinical and behavioural factors.
In Sub-Saharan African, studies have been conducted in countries such as Ethiopia,16
Uganda,17,18 Uganda and Zimbabwe,19 South Africa,3,20 Senegal,12,21,22 Nigeria23 and
Botswana,24 to identify factors affecting adherence to HAART. Some studies were cross-
sectional and did not assess adherence over time. A limitation in some studies was the lack
of multivariate analyses that included an evaluation of interaction terms between
demographic, social and economic factors to control for potential confounding variables.
The cross-sectional work on the analysis of social, demographic, behavioural, economic and
clinical factors influencing initial adherence for this cohort revealed that two-way interaction
terms between age and cell phone ownership, gender and reason for taking an HIV test, as
well as treatment site and income were important.25 Although factors associated with
optimal adherence at the initial stages of therapy give important information, factors that
affect long-term optimal adherence may be more relevant, as lifetime adherence to HAART
is required. It is therefore important to identify factors influencing adherence over time, as
well as the relationships (interactions) between these factors. Studies that evaluate
relationships between factors influencing adherence are limited in the literature, hence the
motivation for this study. The aim of this study was to determine the predictors of optimal




The Centre for the AIDS Programme of Research in South Africa’s (CAPRISA) started a
HAART rollout program in 2004. The CAPRISA AIDS Treatment (CAT) Programme offers
HIV care services at two sites in KwaZulu-Natal, South Africa, namely the eThekwini
Clinical Research site located adjacent to the Prince Cyril Zulu Communicable Disease
Clinic in the center of Durban, and the Vulindlela Clinical Research site, located in a rural
area outside the town of Howick, approximately 95 km from Durban. The programme
started providing free HAART through a President’s Emergency Plan for AIDS Relief
(PEPfAR) grant at a time when access to HAART in the public sector was limited. Adult
patients with a CD4+ count below 200 cells/µL, or patients with World Health Organisation
(WHO) stage 4 of the HIV disease, were eligible for HAART initiation.
During the first month, patients visited the clinic once a week for the first two weeks and
again two weeks later for intensive clinical monitoring. Thereafter, patients visited the
treatment sites monthly to collect their treatment and to undergo a clinical examination.
Prior to HAART initiation, all patients received three sessions of adherence education,
motivation and preparedness training. All patients were on regimens containing two
nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase
inhibitor. Patients in the urban clinic received Efavirenz (EFV), Lamivudine (3TC) and
Didanosine (ddI or ddI-EC). This regimen was chosen as it can be co-administered with
anti-tuberculosis (TB) medication. The regimen in the rural clinic consisted of EFV, 3TC
and Stavudine (d4T), which is recommended according to the South African HIV treatment
guidelines.26 A few pregnant patients (3.8%) received Nevirapine (NVP) rather than EFV.
Patient information was recorded on data collection sheets at the clinics; it underwent two
levels of quality control, and was faxed to a central data management centre. The data
analysed in this study consisted of a retrospective review of patients’ records in the CAT
programme between June 2004 and September 2006. Only patients with pill count data for
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the initial visit, and at least one other clinic visit for the defined study period, were included
in the analysis. The number of follow-up visits differed per patient, as some patients started
treatment earlier and therefore had more visits, while some patients dropped out of the
treatment programme prematurely. Approval for the data collection and analysis was
obtained from the University of KwaZulu-Natal Biomedical Research Ethics Committee
Model variables and measurements
The data routinely collected at the treatment sites included the patients’ demographic details,
medical history, CD4+ cell count and viral load, pill counts, clinical status and a laboratory
safety assessment. For this analysis, the outcome was measured using the pill counts data,
and the covariates were selected from the various aspects of the collected data. The
covariates can be classified as time-independent and time-varying. Measurement and coding
of the outcome and covariates is described below.
Adherence measurement—Adherence to HAART was measured using pill counts
conducted by pharmacists at the treatment sites. Patients were provided with more
medication than required, i.e. tablets were usually dispensed in multiples of 30, whereas
visits were booked in multiples of 28 days. Patients were asked to bring all medication
bottles and unused pills to each clinic visit, but were not told that the returns were to be
counted. Adherence at every visit (monthly, i.e. 28 days) for all the drugs was calculated as
the total number of drugs dispensed, minus the total number of drugs returned, divided by
the total number of days between clinic visits, times the daily dose. This method takes into
account the date of the clinic visits and adjusts for late return to the clinic (meaning pills
would have been missed) and early return to clinic (meaning pills would still be available for
return).
Outcome variable—The outcome was optimal adherence to HAART, and patients were
classified as optimally adherent if they took at least 95% of the prescribed drugs in a given
regimen,4 otherwise, they were considered non-adherent. At each visit, the response variable
was binary, indicating whether a patient was optimally adherent or not (1 = adherence score
of 95% and above, i.e. the patient was optimally adherent; 0 = adherence score less than
95%, i.e. the patient was not optimally adherent).
Time independent covariates—As adherence was monitored very closely for the first
month after initiation of HAART (three visits), compared to subsequent visits, the adherence
for the first month (initial adherence) was treated as a covariate in the analysis. It has been
argued that the use of a baseline response as a covariate in a longitudinal study permits the
use of each subject as their own control to assess the effect of treatment over time.27,28
Initial adherence was calculated as the sum of drugs dispensed in the first month, minus the
sum of drugs returned in the first month (over the three visits), divided by the number of
days between the first and fourth visit multiplied by the daily dose. Those who took 95% of
the prescribed dose were considered adherent (1 = optimal initial adherence; 0 = not optimal
initial adherence).
Baseline demographic and socio-economic variables included in this analysis were age (in
years); gender (1 = female, 0 = male); educational status (2 = no schooling, 1 = primary and
0 = secondary and higher); treatment site (1 = urban, 0 = rural); whether or not a patient
lived with a partner (1 = living with a partner, 0 = not living with a partner); whether or not
the patient was the source of household income (1 = source of household income, 0 = not a
source of household income); access to tap water (1 = yes, 0 = no) and electricity (1 = yes, 0
= no), and whether a patient owned a cell phone (1 = yes, 0 = no). Other variables recorded
at baseline and included were World Health Organisation (WHO) HIV stage (3 = stage 1, 2
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= stage 2, 1 = stage 3 and 0 = stage 4), CD4+ cell count (cells/µL), weight (in kilograms).
Patients were asked why they did an HIV test and their responses included being unwell,
testing for no specific reason, testing because a partner died of HIV, being ill and
unfaithfulness. Reason for testing was therefore classified as follows: (2 = possible exposure
to HIV, 1 = no specific reason and 0 = unwell).
Time varying covariates—Time was measured as a continuous variable representing
monthly follow-up visits to the treatment site. The variable time starts with the value 1 for
the first follow-up visit, 2 for the second visit, up to 17 for the seventeenth follow-up visit.
Weight was measured at every follow-up visit and was modeled as a time-varying covariate.
Data Analysis
Differences in the baseline characteristics of CAT patients excluded and included in the
analysis were compared using the chi-squared test for categorical variables, and the t-test for
the continuous variables. Socio-demographic and clinical characteristics of the study
population were summarised using the median and inter-quartile range (IQR) for continuous
variables and proportions for categorical variables. The trend of optimal adherence over time
was tested using the Cochran-Armitage test for trend.29
To account for multiple measurements of each patient (correlated data), and to allow all
patients, regardless of the number of visits, to be included in the analysis, generalized
estimating equations (GEEs)30 were used to assess factors associated with optimal
adherence over time. Quasi-likelihood function value obtained under the independence
model criterion (QIC)31 was used to select the model with the best fitting correlation
structure. Model selection was done by first including all predictor variables in the model
and then evaluating whether any interaction terms needed to be incorporated into the model.
This was determined by fitting each of the product terms formed from the predictor
variables, one at a time, and keeping the significant terms in the model. As GEE parameters
are estimated using quasi-likelihood procedures, there is no associated likelihood underlying
the model. Therefore, the usual likelihood ratio tests could not be applied to compare
models. However, the generalized Wald test was used for model comparison.32
The GEE method accommodates missing data, however, it yields valid estimates if missing
data can be assumed to be ‘missing completely at random’ (MCAR). This means that
missing values do not depend on the observed (previous) or unobserved outcomes.33,34 A
logistic regression model was used to assess whether dropout in this study is independent of
the previous outcome, i.e. whether the missing data mechanism is MCAR. All statistical




Between June 2004 and September 2006, 1,184 patients were enrolled in the CAT
programme, 411 (35%) at the urban site, and 773 (65%) at the rural site. A total of 688
patients, 369 (54%) from the urban site and 319 (46%) from the rural site were included in
the analysis. Only patients with pill count data for the initial and at least one other clinic
visit were included in the analysis. There were no differences between those included in the
study and those excluded with regard to age (mean: included=34.1 years, excluded=34.0
years; t-value=0.13, p=0.90), gender (males: included=30.0%, excluded=31.8%; chi-square-
value = 0.43, p=0.51) and baseline CD4+ cell count (mean: included=107.6 cells/µL,
excluded=111.5 cells/µL; t-value=0.72, p=0.47). Furthermore, power calculations were
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performed for the available sample size (688 patients) to detect a difference in proportion of
adherent patients between the first follow-up visit and the final follow-up visit of 0.27. With
a sample size of 600, this gave more than 90% power when a test of proportions was done.
Baseline socio-demographic and clinical characteristics of patients
The baseline socio-demographic and clinical characteristics of patients included in the
analysis are presented in Table 1. The median age of patients was 32.5 years (IQR: 28–38
years), 70% were male and 75% were not living with a partner. Over two thirds of the
patients had attained secondary or higher level of education (69%), and 28% of patients
were classified as breadwinners. Over 90% of the patients stayed in households that had
access to tap water and electricity, while 42% of the households had cell phones. At
enrolment, the median weight was 60kg (IQR: 53–69kg), median CD4+ cell count was 108
cells/µL (IQR: 52–159 cells/ µL) and 64% of patients were classified as WHO stage 3. Over
half of the patients (56%) reported to have taken an HIV test as they were not well, while
26% reported no specific reason for testing and 18% took an HIV test as they were
concerned that they had been exposed to HIV. In the initial month of treatment, 79% of the
patients were at least 95% adherent to HAART.
Overall optimal adherence and follow-up visits
The number of follow-up visits ranged between 2 and 17 per patient, with the median of 8
(IQR: 5–12). Figure 1 presents the total number of patients expected at each visit, the
number of patients who actually attended the visit and those who dropped out at each visit.
The proportion of patients who dropped out gradually increased over the follow-up period.
The proportion of patients who were at least 95% adherent (optimally adherent) to HAART
increased from 58% at the first follow-up visit to 86% at the last follow-up visit (Figure 2).
The Cochran-Armitage statistic29 (Z=17.52 and P<0.0001) provides strong evidence of an
increasing adherence rate over time.
Selection of the multivariate model
Using the QIC,31 the correlation structure that fitted the data well was First-Order
Autoregressive (AR1) structure, which reinforces the assumption of equally spaced
measurement occasions.
Cross sectional analysis of predictors of initial optimal adherence showed that two-way
interaction terms between age and cell phone ownership, gender and reason for taking an
HIV test, and treatment site and income were significant.25 Using the same data set, we
evaluated whether these predictors of initial adherence also predicted long-term adherence
using the GEE method. The results were not significant (Wald statistic = 4.78 with 4 degrees
of freedom, P=0.31), indicating no association between long-term optimal adherence and the
interaction terms associated with initial adherence.
To further examine the relationship between long-term optimal adherence and other
variables, a model was built by fitting all the predictor variables (listed in Table 1), followed
by an assessment of whether any interaction terms need to be incorporated into the model.
Consequently, the final model contained five two-way interaction terms and all the predictor
variables. The two-way interactions were between gender and time, treatment site and time,
reported reason for taking an HIV test and time, age and gender, as well as age and
educational attainment (Table 2).
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Predictors of optimal adherence
After controlling for other variables in the model, optimal adherence was significantly
higher when patients had cell phones than when they did not have cell phones [adjusted odds
ratio (aOR) = 1.260, 95% confidence interval (CI): (1.056, 1.503), P = 0.010] and when they
lived with a partner compared to when they did not live with a partner [aOR = 1.335, 95%
CI: (1.097, 1.625), P = 0.004] (Table 2).
Optimal HAART adherence increased on average over time, however, since interactions
with time were significant, the rate at which optimal adherence increased differed by
treatment site, gender and the patient’s reported reason for taking an HIV test. Age
interacted significantly with gender and education. The interaction effects are presented
below.
a) Interaction between gender and time—Optimal HAART adherence increased over
time for both males and females. However, since there was a significant interaction between
gender and time, the rate of increase was not the same for males and females after
controlling for other covariates in the model. The rate of increase was 7.4% higher for
females than for males [aOR = 1.074, 95% CI: (1.034, 1.116); P<0.001] (Table 2).
Estimated probabilities of optimal adherence were higher for males at the beginning of the
follow-up visits, but by the end of the study period (17th follow-up visit), they were similar
for both groups (Figure 3(a)).
b) Interaction between treatment site and time—The rate at which optimal
adherence increased over time differed in the urban and rural treatment sites. After
controlling for other variables in the model, the rate of increase in optimal adherence was
6% higher in the rural treatment site than in the urban treatment site [aOR = 1.06, 95% CI:
(1.002, 1.100); P=0.004] (Table 2). The estimated probability of optimal adherence at the
first follow-up visit was 66% at the rural site and 86% at the urban site (Figure 3(b)). Since
the rate of increase was higher in the rural site relative to the rate of increase in the urban
site, the gap in adherence between the treatment sites gradually decreased over time until, by
the end of the study, the estimated optimal adherence probabilities were similar (at 91% and
92%, respectively).
c) Interaction between reason for taking an HIV test and time—Optimal
adherence increased over time, but the rate at which it increased differed with the patient’s
reported reason for taking an HIV test. The rate of increase in optimal adherence was 5.8%
higher over the study period for patients who tested due to possible exposure to HIV, than
for patients who tested as they were unwell [aOR=1.058, 95% CI: (1.010, 1.108); P=0.016]
(Table 2). There was however no significant difference in the rate of change of optimal
adherence between patients who tested because they were unwell and those who reported no
specific reason for taking an HIV test [Z=−0.43, P=0.666] (Table 2). Further analysis
revealed that the rate of increase in optimal adherence over the study period was 7% higher
for patients who tested due to possible exposure to HIV, than for those who reported no
specific reason for taking an HIV test [aOR=1.069, 95% CI: (1.016, 1.126), P=0.0107).
Figure 3(c) indicates that the estimated probabilities of optimal adherence for patients who
tested as they were unwell, and those who reported no specific reason for taking an HIV test,
were similar throughout the study.
It is again shown in Figure 3(c) that at the beginning of the follow-up period, estimated
probabilities of optimal adherence for patients who tested due to possible exposure to HIV
were less than the estimated probabilities of patients who reported no specific reason for
taking an HIV test, as well as those who tested as they were unwell. However, during the
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middle of the follow-up visits, estimated probabilities were similar for all the reported
reasons. Towards the end of the study, the probabilities of optimal adherence were higher
for patients who tested due to possible exposure to HIV than those who reported no specific
reason for testing for HIV, or those who tested as they were unwell.
d) Interaction between age and gender—Optimal HAART adherence differed by age
for males and females. As the age of patients increased, females tend to adhere better to
HAART than males [aOR: 1.024; 95% CI: (1.006, 1.043), P=0.010]. It is shown in Figure
3(d) that the estimated probabilities of optimal adherence were higher with younger males
than with younger females, whereas with older patients, estimated probabilities were higher
with females than males.
e) Interaction between age and education—Optimal HAART adherence differed by
age at different education levels. Among older patients, those with no schooling were less
likely to achieve optimal HAART adherence than those with secondary and higher
education [OR=0.97; 95% CI: (0.94, 0.99); P=0.012] (Table 2). There was, however, no
significant difference in optimal HAART adherence between patients with secondary
education and patients with primary education, regardless of age [Z=−0.16, P=0.875)]
(Table 2). Further analysis revealed that as patients got older, those with primary education
were more likely to achieve optimal adherence than those with no schooling [aOR=1.03,
95% CI: (1.002, 1.070); P=0.048]. Figure 3(e) indicates that the estimated probabilities of
optimal adherence by patients decreased with age. More specifically, the probability of
optimal adherence for patients with secondary and primary education was similar for all
ages, whereas probabilities of optimal adherence for those with no schooling were higher for
younger ages and lower for older ages, relative to those with primary and secondary
schooling.
Impact of dropout on the analysis
The analysis revealed that dropout did not depend on previous outcome (Chi-squared-value=
0.103 with 1 degree of freedom; P = 0.748). It can therefore be concluded that MCAR holds
and as a result, GEE method yielded valid estimates.
Discussion
Consistent with results from recent longitudinal studies in Sub-Saharan Africa,16,19 the
findings showed that optimal HAART adherence increased with time, indicating that
programmatic interventions conducted during the CAT programme may have had a positive
impact on adherence. These interventions included patients being exposed to on-going peer
education when queuing for services within the clinic, and through one-on-one session with
a peer educator at the end of the clinic visit after the pills were collected. Every six months,
patients received individual education on adherence maintenance. This highlights the
importance of prioritising adherence counseling when setting up new HAART clinics. These
results reinforce the message that it is possible to achieve and sustain high levels of HAART
adherence in Sub-Saharan Africa, given strong support measures.
Studies have consistently shown that demographic characteristics are generally poor
predictors of HAART adherence.35,36 However, the results from this study demonstrate
that demographic factors predict HAART adherence through interactions among themselves
or with other variables. For instance, an interaction between age and educational attainment
predict HAART adherence. More specifically, as patients get older, adherence decreases
over time, and the decrease is more pronounced with patients who have no schooling and in
male patients.
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HAART adherence increased over time but at different rates in males and females. Males
had higher adherence at the beginning of the follow-up period but by the end of the study
period, adherence was similar between males and females. This might be explained by social
and behavioural factors associated with HAART adherence being different in males and
females.37 For instance, women are generally responsible for care-giving duties which
might hamper adherence at the beginning of treatment, until they get used to the new routine
of taking their own medication.37,38
HAART adherence has been higher in urban clinics than in rural clinics, which has been
attributed to the latter being less well resourced.39 However, the rate at which adherence
increases with time is higher in the rural clinic than in the urban clinic. Studies have shown
that in rural settings, optimal adherence tends to increase over time.40 Since rural
populations live in a more communal setting, the positive impact of HAART on HIV
positive-patients might be more visible, which may positively influence optimal adherence
to HAART.
Patients who lived with a partner adhered better to HAART than those who lived with no
partner. Lack of social support has been associated with a decrease in adherence41 and
living with a partner has been associated with increased social support and optimal
adherence.42 Furthermore, cell phone ownership enhanced long-term optimal HAART
adherence. This reinforces proposed interventions of providing memory aids for dosing
times that include the use of new technologies such as reminders through cell phones,43–47
and verbal or text messaging for check-up reminders and general adherence messages.48
Three shortcomings are acknowledged in our research. Firstly, adherence was assessed only
through pill counts. Pill counts method is attractive due to its simplicity and empirical
nature; however, it has disadvantages that include patients switching medicines between
bottles or discarding pills before visits.47 Despite these problems, it has been shown that pill
counts method has a strong linear relationship with viral load.49
Secondly, interactions between variables were identified using the data and model fit
techniques. The interactions were not pre-specified or expected during data collection.
Detailed information on why these interactions influenced adherence was therefore not
collected, and the reasons for some of these findings cannot be explained.
Thirdly, an equal interval (monthly) between successive follow-up visits by all patients was
assumed. In reality, some patients visited the clinic a number of days earlier or later than
scheduled appointments. However, the impact of this assumption on the analysis is
negligible for a number of reasons. The patients in the CAT programme have shown
excellent clinic attendance with scheduled appointment. In addition, patients were given 2-
day buffer stock with each supply to cover appointment delays and this was accounted for in
calculating the adherence rate. Generally, when we say monthly data, we do not expect an
equal number of days in every month. Furthermore, the effect of unequally spaced interval
correlation structures was tested using QIC and was found to be insignificant, which
reinforces the assumption of equal interval between clinic visits.
The study showed that HAART adherence increased over time on average, however, the rate
at which it increased differed by treatment site, gender and the patient’s reported reason for
taking an HIV test. Consequently, due attention should be paid to address the specific needs
of each group of patients, specifically with respect to urban-rural and gender differentials.
HAART adherence over time increased for patients with cell phones and patients living with
a partner, and decreased as age of patients’ with no schooling increased. HAART programs
need to take these factors into account in the design and implementation of long-term
adherence strategies. Specific groups of patients at risk for less than optimal adherence
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should be targeted with long-term adherence boosting sessions tailored to their specific
needs.
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Table 1
Baseline socio-demographic and clinical characteristics of the patients
Characteristics value
Age (years)





No schooling   74 (12)
Primary 116 (19)
Secondary and higher 429 (69)
Treatment site, n (%)
Urban site 369 (54)
Rural site 319 (46)
Source of household income, n (%)
Source of income 186 (28)
Not source of income 489 (72)
Living with or without a partner, n (%)
Living with a partner 168 (25)
Living without a partner 510 (75)
Household with or without electricity, n (%)
Yes 607 (91)
No   63 (9)
Access to tap water, n (%)
Yes 611 (91)
No   59 (9)
Cell phone ownership, n (%)
Yes 281 (42)
No 389 (58)
WHO stage of HIV disease, n (%)
Stage 1   71 (10)
Stage 2 121 (16)
Stage 3 438 (64)
Stage 4   58 (8)
Reason for taking HIV test, n (%)
Unwell 374 (56)
Possible exposure to HIV 170 (26)
No specific reason 121 (18)
Initial (baseline) optimal adherence, n (%)
      Optimally adherent 546 (79)
      Not optimally adherent 142 (21)
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Table 2
Adjusted odds ratio (aOR) from the GEE model with associated 95% confidence intervals (CI)
Parameter aOR (95% CI) Pvalue
Intercept 1.802 (0.832, 3.903) 0.146
Age 0.988 (0.972, 1.004) 0.147
Gender (ref = male)
Female 0.030 (0.155, 0.591) 0.001
Education (ref = secondary and above)
No schooling 5.038 (1.837, 13.82) 0.002
Primary 1.104 (0.378, 3.223) 0.856
Treatment site (ref = rural site)
Urban site 3.233 (2.355, 4.438) <.001
Source of household income (ref=source)
Not source of income 1.008 (0.828, 1.229) 0.934
Access to tap water (ref = no)
Yes 1.114 (0.831, 1.494) 0.469
Household with electricity (ref = no)
Yes 1.004 (0.786, 1.283) 0.975
Cell phone ownership (ref = no)
Yes 1.260 (1.056, 1.503) 0.010
Reason for taking an HIV test (ref = unwell)
No specific reason 0.973 (0.685, 1.381) 0.877
Possible exposure to HIV 0.615 (0.431, 0.877) 0.007
Staying with a partner (ref = no)
Yes 1.335 (1.097, 1.625) 0.004
WHO staging of HIV disease (ref = stage4)
Stage 1 0.716 (0.486, 1.054) 0.091
Stage 2 0.778 (0.554, 1.092) 0.147
Stage 3 0.898 (0.660, 1.221) 0.492
Baseline CD4+ cell count 1.000 (0.998, 1.001) 0.532
Initial optimal adherence (ref = not adherent)
Adherent 0.869 (0.704, 1.072) 0.190
Time (visit) 1.105 (1.059, 1.153) <.001
Baseline weight (0.996) (0.981, 1.010) 0.557
Weight at follow-up visits 1.001 (0.987, 1.015) 0.890
Time*gender (ref = male)
Female 1.074 (1.034, 1.116) <.001
Time*treatment site (ref = rural site)
Urban site 0.945 (0.908, 0.982) 0.004
Time*reason for taking the test (ref = unwell)
No specific reason 0.989 (0.947, 1.033) 0.624
Possible exposure to HIV 1.058 (1.010, 1.108) 0.018
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Parameter aOR (95% CI) Pvalue
Age*gender (ref = male)
Female 1.024 (1.006, 1.043) 0.010
Age*education (ref = secondary and above)
No schooling 0.968 (0.943, 0.993) 0.012
Primary 0.998 (0.972, 1.025) 0.875
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